Timing is the biggest challenge when it comes to navigating the nascent schedule 3 cannabidiol (CBD) supplement go-to-market system, says Bod Australia, which is aiming to be one of the first to launch such a product in Australia.
In this round up, we present scientific findings from both the academia and the industry, including Bod Australia’s discovery of protein carrier for CBD skin care, Malaysian firm Davos Life Science exploring the potential of tocotrienols for IBS, ginseng’s...
Bod Australia has stated that the absence of a clear pathway to market for its CBD products explains why APAC is “not yet on the radar” for its recently announced distribution deal with NewH2.